NEW HAVEN, Conn., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the 25 th Annual Credit Suisse Healthcare Conference on Monday,
Janssen HCV triple combination candidate JNJ-4178 reported 100% SVR12 after 6 weeks of therapy; global phase IIB study to begin 4Q 2016 Achillion's phase I MAD study with oral factor D inhibitor ACH-4471 ongoing; strong complement inhibition observed in in vivo and ex vivo assays Company advancing
NEW HAVEN, Conn., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two abstracts have been accepted for poster presentation at the 58th Annual Meeting of the American Society of Hematology (ASH) in San Diego, CA, December 3 - 6, 2016. "The data
- Janssen initiates dosing of patients in OMEGA-1: Phase 2b study evaluating six- and eight-week treatment durations with JNJ-4178, a 3DAA combination of odalasvir, simeprevir, and AL-335, for the treatment of chronic HCV - NEW HAVEN, Conn., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Achillion
SAN DIEGO, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced novel research into complement biology that both expands the understanding of this important emerging area and demonstrates the potential advantage of factor D inhibitors like the company's
NEW HAVEN, Conn., Dec. 28, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it has received a $15 million milestone payment from Janssen Research & Development, LLC., part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), related to
NEW HAVEN, Conn., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the Leerink Partners 6 th Annual Global Healthcare Conference on
Complement factor D inhibitor program on track for initiation of ACH-4471 phase II trial for treatment-naïve PNH patients during the first half of 2017 Expanding complement platform includes internally discovered next-generation oral factor D inhibitors with the goal of advancing at least one into
Three-year study commenced to include up to 400 patients Natural history studies track course of a disease over time; can inform and support development and approval of new treatments for patients C3 glomerulopathy currently has no cure or approved treatment; affects about 8,000 people across
NEW HAVEN, Conn., March 21, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued the first U.S. Patent to Achillion resulting from its complement factor D research program. U.S. Patent No.